Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 78

1.

TH-302, a hypoxia-activated prodrug with broad in vivo preclinical combination therapy efficacy: optimization of dosing regimens and schedules.

Liu Q, Sun JD, Wang J, Ahluwalia D, Baker AF, Cranmer LD, Ferraro D, Wang Y, Duan JX, Ammons WS, Curd JG, Matteucci MD, Hart CP.

Cancer Chemother Pharmacol. 2012 Jun;69(6):1487-98. doi: 10.1007/s00280-012-1852-8. Epub 2012 Mar 2.

2.

Selective tumor hypoxia targeting by hypoxia-activated prodrug TH-302 inhibits tumor growth in preclinical models of cancer.

Sun JD, Liu Q, Wang J, Ahluwalia D, Ferraro D, Wang Y, Duan JX, Ammons WS, Curd JG, Matteucci MD, Hart CP.

Clin Cancer Res. 2012 Feb 1;18(3):758-70. doi: 10.1158/1078-0432.CCR-11-1980. Epub 2011 Dec 19.

3.

C-reactive protein as a prognostic marker for men with androgen-independent prostate cancer: results from the ASCENT trial.

Beer TM, Lalani AS, Lee S, Mori M, Eilers KM, Curd JG, Henner WD, Ryan CW, Venner P, Ruether JD, Chi KN; ASCENT Investigators.

Cancer. 2008 Jun;112(11):2377-83. doi: 10.1002/cncr.23461.

4.

High dose calcitriol may reduce thrombosis in cancer patients.

Beer TM, Venner PM, Ryan CW, Petrylak DP, Chatta G, Dean Ruether J, Chi KN, Curd JG, DeLoughery TG.

Br J Haematol. 2006 Nov;135(3):392-4. Epub 2006 Sep 19.

PMID:
16984385
5.

Genentech and breast cancer advocacy.

Shak S, Bales R, Baughman SA, Curd JG, Fuchs HJ, Perry C, Teeter G, Leber L.

Breast Dis. 1998 Dec;10(5-6):61-4. No abstract available.

PMID:
15687586
6.

Prolonged, complete remission after 2-chlorodeoxyadenosine therapy in a patient with refractory essential mixed cryoglobulinemia.

Lee TC, Miller WE, Curd JG, Piro LD, Saven A.

Mayo Clin Proc. 1996 Oct;71(10):966-8.

PMID:
8820771
7.

A systematic approach to disorders of the cervical spine.

Thorne RP, Curd JG.

Hosp Pract (Off Ed). 1993 Jun 15;28(6):49-58. Review.

PMID:
8509482
8.

Atlantoaxial lateral mass osteoarthritis. A frequently overlooked cause of severe occipitocervical pain.

Star MJ, Curd JG, Thorne RP.

Spine (Phila Pa 1976). 1992 Jun;17(6 Suppl):S71-6.

PMID:
1631722
9.

Autoantibodies to native myeloperoxidase in patients with pulmonary hemorrhage and acute renal failure.

Roberts DE, Peebles C, Curd JG, Tan EM, Rubin RL.

J Clin Immunol. 1991 Nov;11(6):389-97.

PMID:
1662224
10.

Extraspinal causes of lumbosacral radiculopathy.

Kleiner JB, Donaldson WF 3rd, Curd JG, Thorne RP.

J Bone Joint Surg Am. 1991 Jul;73(6):817-21.

PMID:
1830051
11.

Radiating leg pain in the older patient.

Thorne RP, Curd JG.

Hosp Pract (Off Ed). 1991 Mar 15;26(3):61-4, 69-72.

PMID:
1900853
12.
13.

Potent toxicity of 2-chlorodeoxyadenosine toward human monocytes in vitro and in vivo. A novel approach to immunosuppressive therapy.

Carrera CJ, Terai C, Lotz M, Curd JG, Piro LD, Beutler E, Carson DA.

J Clin Invest. 1990 Nov;86(5):1480-8.

14.

Sulfonamides as antiinflammatory agents in the treatment of Wegener's granulomatosis.

Roberts DE, Curd JG.

Arthritis Rheum. 1990 Oct;33(10):1590-3. No abstract available.

PMID:
2222542
15.

The clinical significance of iC3b neoantigen expression in plasma from patients with systemic lupus erythematosus.

Negoro N, Okamura M, Takeda T, Koda S, Amatsu K, Inoue T, Curd JG, Kanayama Y.

Arthritis Rheum. 1989 Oct;32(10):1233-42.

PMID:
2803326
16.

Diagnosis and management of lumbar disk disease.

Curd JG, Thorne RP.

Hosp Pract (Off Ed). 1989 Sep 15;24(9):135-9, 142, 145-8. Review.

PMID:
2527861
17.

High-molecular-weight kininogen is cleaved in active erythema multiforme.

Lang DM, Sugimoto SL, Curd JG, Christiansen SC, Zuraw BL.

J Allergy Clin Immunol. 1989 Apr;83(4):802-10.

PMID:
2708741
18.

Detection and quantitation of cleaved and uncleaved high molecular weight kininogen in plasma by ligand blotting with radiolabeled plasma prekallikrein or factor XI.

Lämmle B, Zuraw BL, Heeb MJ, Schwarz HP, Berrettini M, Curd JG, Griffin JH.

Thromb Haemost. 1988 Apr 8;59(2):151-61.

PMID:
3388291
19.

Complement profiles in acute post-streptococcal glomerulonephritis.

Wyatt RJ, Forristal J, West CD, Sugimoto S, Curd JG.

Pediatr Nephrol. 1988 Apr;2(2):219-23.

PMID:
3153014
20.

Underlying complement deficiency in patients with disseminated gonococcal infection.

Ellison RT 3rd, Curd JG, Kohler PF, Reller LB, Judson FN.

Sex Transm Dis. 1987 Oct-Dec;14(4):201-4.

PMID:
2830678
21.

Complement activation in IgA nephropathy.

Wyatt RJ, Kanayama Y, Julian BA, Negoro N, Sugimoto S, Hudson EC, Curd JG.

Kidney Int. 1987 Apr;31(4):1019-23.

22.

Interaction of pathogenic and nonpathogenic Entamoeba histolytica with human complement.

Reed SL, Gault M, Gillin FD, Gigli I, Braude AI, Curd JG, Sargeaunt PG.

Arch Invest Med (Mex). 1987 Apr-Jun;18(2):141-9. No abstract available.

PMID:
2889433
23.

Effects of recombinant human interferons on rheumatoid arthritis B lymphocytes activated by Epstein-Barr virus.

Lotz M, Tsoukas CD, Curd JG, Carson DA, Vaughan JH.

J Rheumatol. 1987 Feb;14(1):42-5.

PMID:
3033238
24.
25.

Different patterns of C3 and C4 activation in the varied types of juvenile arthritis.

Miller JJ 3rd, Olds LC, Silverman ED, Milgrom H, Curd JG.

Pediatr Res. 1986 Dec;20(12):1332-7.

PMID:
3099253
27.

Meningococcemia and acquired complement deficiency. Association in patients with hepatic failure.

Ellison RT 3rd, Mason SR, Kohler PF, Curd JG, Reller LB.

Arch Intern Med. 1986 Aug;146(8):1539-40.

PMID:
3729633
28.

Complement activation in vitro by antiplatelet antibodies in chronic immune thrombocytopenic purpura.

Tsubakio T, Tani P, Curd JG, McMillan R.

Br J Haematol. 1986 Jun;63(2):293-300.

PMID:
3718872
29.

Complement-activating abilities of defined antinuclear antibodies.

Kanayama Y, Peebles C, Tan EM, Curd JG.

Arthritis Rheum. 1986 Jun;29(6):748-54.

PMID:
3487323
30.

Sjögren's syndrome. Proposed criteria for classification.

Fox RI, Robinson CA, Curd JG, Kozin F, Howell FV.

Arthritis Rheum. 1986 May;29(5):577-85.

PMID:
3718551
31.

Serologic changes during induction of lupus-like disease by procainamide.

Rubin RL, Nusinow SR, Johnson AD, Rubenson DS, Curd JG, Tan EM.

Am J Med. 1986 May;80(5):999-1002.

PMID:
3706385
32.

Direct quantitation of activated C3 in human plasma with monoclonal anti-iC3b-C3d-neoantigen.

Kanayama Y, Kurata Y, McMillan R, Tamerius JD, Negoro N, Curd JG.

J Immunol Methods. 1986 Apr 3;88(1):33-6.

PMID:
2420896
33.

Association of systemic immune complexes, complement activation, and antibodies to Pseudomonas aeruginosa lipopolysaccharide and exotoxin A with mortality in cystic fibrosis.

Moss RB, Hsu YP, Lewiston NJ, Curd JG, Milgrom H, Hart S, Dyer B, Larrick JW.

Am Rev Respir Dis. 1986 Apr;133(4):648-52.

PMID:
3083745
34.

Cloning and sequence determination of a human rheumatoid factor light-chain gene.

Jirik FR, Sorge J, Fong S, Heitzmann JG, Curd JG, Chen PP, Goldfien R, Carson DA.

Proc Natl Acad Sci U S A. 1986 Apr;83(7):2195-9.

35.

Activation of complement by pathogenic and nonpathogenic Entamoeba histolytica.

Reed SL, Curd JG, Gigli I, Gillin FD, Braude AI.

J Immunol. 1986 Mar 15;136(6):2265-70.

PMID:
2869084
36.

Effects of protamine administration after cardiopulmonary bypass on complement, blood elements, and the hemodynamic state.

Kirklin JK, Chenoweth DE, Naftel DC, Blackstone EH, Kirklin JW, Bitran DD, Curd JG, Reves JG, Samuelson PN.

Ann Thorac Surg. 1986 Feb;41(2):193-9.

PMID:
3947172
37.

Decreased synthesis of serum carboxypeptidase N (SCPN) in familial SCPN deficiency.

Mathews KP, Curd JG, Hugli TE.

J Clin Immunol. 1986 Jan;6(1):87-91.

38.

Fluorescent antinuclear antibodies and anti-SS-A/Ro in patients with immune thrombocytopenia subsequently developing systemic lupus erythematosus.

Anderson MJ, Peebles CL, McMillan R, Curd JG.

Ann Intern Med. 1985 Oct;103(4):548-50. No abstract available.

PMID:
3898952
39.

The dermal manifestations of vasculitis. A clinical approach to diagnosis and treatment.

Nusinow SR, Izuno GT, Curd JG.

Postgrad Med. 1985 Sep 1;78(3):122-4, 127-35. No abstract available.

PMID:
2863815
40.

Platelet-associated complement in chronic ITP.

Kurata Y, Curd JG, Tamerius JD, McMillan R.

Br J Haematol. 1985 Aug;60(4):723-33.

PMID:
4040770
41.

The hereditary and acquired deficiencies of complement.

Nusinow SR, Zuraw BL, Curd JG.

Med Clin North Am. 1985 May;69(3):487-504. Review.

PMID:
3892188
42.

Increased von Willebrand factor antigen in the plasma of patients with vasculitis.

Nusinow SR, Federici AB, Zimmerman TS, Curd JG.

Arthritis Rheum. 1984 Dec;27(12):1405-10.

PMID:
6508862
43.

Thoracic duct drainage in rheumatoid arthritis.

Vaughan JH, Fox RI, Abresch RJ, Tsoukas CD, Curd JG, Carson DA.

Clin Exp Immunol. 1984 Dec;58(3):645-53.

44.

Studies of complement activation and IgG subclass restriction of anti-thyroglobulin.

Adler TR, Beall GN, Curd JG, Heiner DC, Sabharwal UK.

Clin Exp Immunol. 1984 May;56(2):383-9.

45.

Aspirin-sensitive asthma and rhinosinusitis: current concepts and recent advances.

Lumry WR, Curd JG, Stevenson DD.

Ear Nose Throat J. 1984 Feb;63(2):66, 68-70, 72-4 passim. No abstract available.

PMID:
6705723
46.

The absence of detectable complement activation in aspirin-sensitive asthmatic patients during aspirin challenge.

Pleskow WW, Chenoweth DE, Simon RA, Stevenson DD, Curd JG.

J Allergy Clin Immunol. 1983 Nov;72(5 Pt 1):462-8.

PMID:
6630797
47.

An enzyme-linked immunosorbent assay for platelet compatibility testing.

Tamerius JD, Curd JG, Tani P, McMillan R.

Blood. 1983 Oct;62(4):744-9.

48.

Immunodiffusion assay of C1 inhibitor function in serum: prospective analysis in angioedema-urticaria.

Yelvington M, Prograis LJ Jr, Pizzo CJ, Curd JG.

Am J Clin Pathol. 1983 Sep;80(3):309-13.

PMID:
6410904
49.

Association of rheumatoid factor with complement activation in rheumatoid arthritis and other diseases.

Reyes PA, Maluf JG, Curd JG, Vaughan JH.

Clin Exp Immunol. 1983 Aug;53(2):391-6.

50.

The plasma contact system in atopic asthma.

Lasser EC, Lang JH, Curd JG, Cochrane CG, Lyon SG, Howard MM, Hamblin AE, Revak SD.

J Allergy Clin Immunol. 1983 Jul;72(1):83-8.

PMID:
6189880

Supplemental Content

Support Center